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with diabetes induced by streptozotocin after uninephrec- condition, grew at the same rate as untreated controls,
and developed no anemia (hematocrit  42  1% intomy prevented albuminuria for a long period.
We also verified whether MMF prevents development diabetic treated vs. 44  1% in untreated at 8 months of
observation, P  0.1). We avoided higher doses, which,of anti-glomerular basement membrane (GBM) antibody-
induced glomerulonephritis. Experimental nephritis in in pilot studies, were systematically associated with anemia,
stunted growth, and poor general condition. MMF hasWKY/NCrj (MHC haplotype; RT1l) rats was induced by
an intraperitoneal injection of anti-GBM antibody (SR2). been associated with reversible anemia in transplant pa-
tients, suggesting that it may indeed depress the ery-Then, the animals were given 20 mg/kg/day of oral MMF
(treated group) or normal saline (control group) for 2 throid series [1]. We believe this is dose-dependent, and
that MMF doses should be carefully titrated if this andweeks. The results showed MMF significantly prevented
urinary protein excretion (treated group vs. control other untoward effects are to be avoided. We are un-
aware of data on variable susceptibility among rat strains,group, 9.4  4.3/creatinine vs. 21.7  4.3/creatinine).
However, daily administration of MMF significantly re- although this is certainly possible.
duced the hematocrit level (24.0 0.8% vs. 41.7 1.5%)
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ferent rat strains. Few adverse effects occurred when Sa˜o Paulo, Brazil
we administered 20 mg/kg/day of MMF to Lewis rats
Correspondence to Ricardo Utimura, M.D., Renal Division, Depart-(haplotype; RT1l) in another experimental model. It was
ment of Clinical Medicine, University of Sa˜o Paulo, Sa˜o Paulo, SP, Brazil.
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administered to BN rats (RT1n), no adverse effects oc-
curred [3]. Because MMF is a critical dose drug and REFERENCES
markedly affected by sensibility, there may be differ-
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Although on a general basis this possibility cannot be1. Shaw LM, Korecka M, DeNofrio D, Brayman KL: Pharmaco-
kinetic, pharmacodynamic, and outcome investigations as the basis ruled out, we believe that prolonged QT interval does
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prevents the development of glomerular injury in experimental dia- Moreover, the level of corrected prolonged QT interval
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patients included in the study. Finally, to the best of our
Reply from the Authors knowledge, there is no report of sudden death in patients
with Bartter’s or Gitelman’s syndrome. In our cohort ofWe wish to thank Dr. Takeda and his colleagues for
their remarks. In the study in question, and in prior Bartter’s patients, whose genetic characterization later
allowed the diagnosis of affected by Bartter’s or Gitel-studies of the 5/6 renal ablation and the chronic nitric
oxide inhibition models, we always administered myco- man’s syndrome, however, we reported specific abnor-
malities of cardiac function, independent of hypoka-phenolate mofetil (MMF) at 10 mg/kg/day. At this dose,
diabetic rats ate normally, remained in good “clinical” lemia, characterized by the inability to adequately recruit
